News

2009-02-25 Poland: Selvita responsible for antibacterial peptide analysis in a pan-European consortium

Selvita will participate in an SME-driven collaborative research project within a pan-European consortium to develop innovative technology and equipment for solid phase peptide synthesis. During the course of this 3 year, 3 million euro global project, Selvita will be in charge of performing analysis of available sequences of antibacterial peptides, searching for peptide motifs responsible for induction of cytokines and predicting in silico the antibacterial activity and cytotoxicity of these peptides.

The recent selection of Selvita in this prestigious research consortium, spanning four different countries exemplifies our strengths to translate scientific discoveries into meaningful technologies, said Dr Nicolas Beuzen, Chief Scientific Officer at Selvita. The PEPLASER project, funded by the European Union through the 7th Framework Program, will allow to improve the competitiveness of our industry, as well as to guarantee the development of new technologies. This project should boost the field of proteomics in a similar way than DNA microarrays did with the field of genomics, added Dr Mateusz Nowak, Project Leader at Selvita.

A strong scientific structure has gathered from eleven institutions in four European countries (Germany, Austria, Poland and Bulgaria). PEPLASER is being coordinated by Dr Frank Breitling, one of the pioneers of antibody technologies, and co-inventor of the laser printed peptide array from German Cancer Research Center in Heidelberg (DKFZ), which ranks among the world top five molecular biology institutes. In Poland, the project will also be conducted in Pozna? by BioInfobank.

Izabela Klockowska
Source: www.selvita.com